The role of antibodies ofCD 15 as diagnostic markers of Hodgkin's disease was assessed from a review of the literature. A total of 571 cases of Hodgkin's disease and 386 cases of non- Hodgkin's lymphoma were included. The sensitivity of CD15 in detecting cases of Hodgkin's disease was 80% or 91% if cases of lymphocyte predominant Hodgkin's disease were excluded. The specificity of CD15 was only 80.6%, or in other words, 19.4% of cases of non-Hodgkin's lymphoma were CD15 positive. In an ideal test both the sensitivity and specificity would be 100% and if the test performance were no better than chance then they would both be 50%. It is concluded that CD15 immunostaining cannot be regarded as a sensitive or specific marker of Hodgkin's disease. Application of this formal method of analysis to other immunohistological reagents and panels of antibodies is discussed.
CITATION STYLE
Hall, P. A., & D’Ardenne, A. J. (1987). Value of CD15 immunostaining in diagnosing Hodgkin’s disease: A review of published literature. Journal of Clinical Pathology. BMJ Publishing Group. https://doi.org/10.1136/jcp.40.11.1298
Mendeley helps you to discover research relevant for your work.